HC Wainwright & Co. Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $90

Benzinga · 4d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $90.